Drugs.com

MARCH 25, 2024

MONDAY, March 25, 2024 — Men with prostate cancer treated at hospitals participating in a special drug-pricing program were more likely to stick to their therapy than patients elsewhere, new research reveals.The federal 340B Drug Program requires.

Treatment 147

Treatment Hospitals Therapies Research 147

Drug Target Review

NOVEMBER 17, 2023

They do not induce ‘graft versus host’ disease when transplanted for allogeneic therapy and there appears little sign of immune rejection. Peripheral blood NK cells have been used in allogeneic cancer therapies and shown to be safe. NK cells can be readily extracted from umbilical cord blood or peripheral blood of adult donors.

Therapies 103

Therapies Clinical Trials Immune Response Trials 103

DrugBank

JUNE 13, 2024

  Gene Therapy: Reprogramming the Body's Cellular Code    Gene therapy is an exciting field that treats diseases at their genetic roots.    A key part of gene therapy is efficiently delivering the therapeutic genetic material directly into target cells.

Therapies 98

Therapies Drugs DNA Treatment 98

SCIENMAG: Medicine & Health

JUNE 30, 2023

The study involved ArteraAI, a developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, and other researchers including those from University Hospitals (UH) Seidman Cancer Center. The information […]

Hospitals 85

Hospitals Research Therapies 85

SCIENMAG: Medicine & Health

JUNE 18, 2023

A three-year-long retrospective cohort study of a single Atlanta hospital’s patient population found transgender and gender-diverse teenagers rarely chose to discontinue gender-affirming hormone therapy, according to a study being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.

Therapies 62

Therapies Hospitals 62

Drug Target Review

FEBRUARY 1, 2024

Historically, what has limited investor interest in funding neurological and psychiatric therapies in development? Investors have historically taken a ‘guilty until proven innocent’ approach to investing in neuroscience therapies. All stakeholders have benefited from these innovations.

Therapies 105

Therapies Drug Development Disease Clinical Development 105

SCIENMAG: Medicine & Health

JULY 14, 2023

CLEVELAND – A new study from University Hospitals (UH) Connor Whole Health describes the scope and integration of their music therapy program within10 UH medical centers.

Therapies 66

Therapies Hospitals Research 66

Drug Discovery Today

MAY 21, 2020

Translational Programme established for FIH late stage HER2 positive breast cancer in Q4 2020

Hospitals 100

Hospitals Production Therapies 100

Conversations in Drug Development Trends

OCTOBER 14, 2024

Given the complexity and widespread impact of autoimmune and bone health conditions, developing new therapies is essential. These therapies represent a significant shift from traditional treatments, offering patients a higher chance of long-term symptom relief and improved quality of life.

Research 52

Research Clinical Trials Therapies Immune Response 52

SCIENMAG: Medicine & Health

JULY 21, 2023

The preclinical study showed that injecting ovarian tissue-derived differentiated induced pluripotent stem cells can restore hormone production and fertility in mice with premature ovarian failure related to genetic diseases and cancer treatment A new study by investigators from Brigham and Women’s Hospital, a founding members of the Mass General Brigham (..)

Therapies 80

Therapies Research Hospitals Treatment 80

Fierce BioTech

AUGUST 31, 2023

How Continuous Safety Monitoring Can Reduce Hospital Stays for High-Risk Oncology Patients swheeler Thu, 08/31/2023 - 14:13 Fri, 10/06/2023 - 14:00 Resource Type Webinar Sridevi Rajeeve, MD Nicole Zahradka, PhD Duration 45 Minutes Cellular therapy products such as CAR-T show promising clinical efficacy in fighting cancer.

Hospitals 52

Hospitals Therapies Production Research 52

Drug Channels

DECEMBER 19, 2021

Ring in 2022 with these noisemakers from the Drug Channels party bag: Hospitals earn incredible markups on CAR-T therapies Utilization management booms Health plans often ignore clinical guidelines Benefit designs flummox physicians Plus: an awesomely concise summary of U.S. Happy New Year, everyone! health insurance.

Hospitals 98

Hospitals Therapies Drugs 98

The Pharma Data

DECEMBER 28, 2020

Women Have Lower Survival to Hospital Discharge After OHCA. 28, 2020 — Women have significantly lower survival to hospital discharge among out-of-hospital cardiac arrest patients, according to a study published online Dec. In women, survival to hospital discharge was significantly lower (adjusted odds ratio, 0.78).

Hospitals 52

Hospitals Therapies Research 52

KIF1A

APRIL 25, 2024

She is scheduled to be the 2nd patient in the world to receive ASO therapy for KAND. March 2023 – We met with n-Lorem and found out Susannah’s ASO (1st KAND patient to receive ASO therapy for KAND) would work for Sloane. Sloane is an adorable 3 year old with KAND. Hello KIF1A Community! We are also paying for our housing.

Therapies 52

Therapies FDA Approval FDA Treatment 52

Drug Target Review

AUGUST 29, 2024

What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies? MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs.

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

The Pharma Data

DECEMBER 28, 2020

LY-CoV555 Not Efficacious for Hospitalized Patients With COVID-19. 28, 2020 — The neutralizing monoclonal antibody LY-CoV555, given in conjunction with remdesivir, is not efficacious for hospitalized patients with COVID-19 without end-organ failure, according to a study published online Dec. Professional. MONDAY, Dec.

Hospitals 52

Hospitals Science Therapies Trials 52

The Pharma Data

OCTOBER 22, 2020

22, 2020 — Kids with autism or attention-deficit hyperactivity disorder ( ADHD ) go to the hospital more in their first year of life than children without these conditions, according to a new study. Children with ADHD had more blood transfusions, hospital admissions and emergency department visits. THURSDAY, Oct.

Hospitals 52

Hospitals Doctors Science Therapies 52

ASPET

AUGUST 2, 2024

Based on previous studies, we hypothesized that vascular senescence increases the risk of bleeding during warfarin therapy. Vascular senescence, marked by vascular stiffening and endothelial dysfunction, has an unclear effect on the efficacy and safety of warfarin.

Therapies 100

Therapies Hospitals International 100

The Pharma Data

OCTOBER 19, 2020

19, 2020 — Children with autism spectrum disorder (ASD) and/or attention-deficit/hyperactivity disorder ( ADHD ) have more doctor and hospital visits during infancy, according to a study published online Oct. MONDAY, Oct. 19 in Scientific Reports. Engelhard, M.D., and ophthalmology (aOR, 3.1).

Doctors 52

Doctors Hospitals Therapies Pharmaceuticals 52

Broad Institute

AUGUST 19, 2024

Jude Children’s Research Hospital have discovered that oleic acid, one of the most abundant fatty acids in the body, restores a healthy balance of vaginal microbes in a laboratory model of BV. Jude Children’s Research Hospital, the Bill & Melinda Gates Foundation, and other sources. Paper cited Zhu M et al.

Hospitals 121

Hospitals Treatment Medical Schools Science 121

The Pharma Data

APRIL 19, 2022

Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies. — Scalable and Adaptable Facility Provides Flexibility for Current and Future Cell Therapy Innovation. The site will produce Kite’s FDA approved CAR T-cell therapy used to treat blood cancer.

FDA Approval 52

FDA Approval Therapies FDA Hospitals 52

Drug Target Review

DECEMBER 16, 2024

This field allowed me the privilege of tending to children in the hospital and building long-term relationships with them and their families. Throughout her academic career, she worked in translational and clinical research, focusing on novel therapies for pediatric cancers.

Medical Schools 52

Medical Schools Clinical Research Drug Development Trials 52

SCIENMAG: Medicine & Health

JUNE 14, 2023

Three young patients with relapsed T-cell leukaemia have now been treated with base-edited T-cells, as part of a ‘bench-to-bedside’ collaboration between UCL and Great Ormond Street Hospital for Children (GOSH).

Therapies 58

Therapies Clinical Trials Hospitals Trials 58

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. who require oxygen therapy due to COVID-19, OR. Yancopoulos , M.D.,

Hospitals 52

Hospitals Production Clinical Trials Virus 52

Broad Institute

FEBRUARY 7, 2024

It examined endothelial mechanisms unrelated to lipid metabolism (a known driver of CAD risk with effective therapies, like statins) in hopes of uncovering other mechanisms driving CAD risk for which therapies may yet be developed. “Now

Disease 105

Disease Hospitals Medical Schools Therapies 105

Drug Target Review

JANUARY 12, 2024

This one size fits all approach to drug prescribing still pervades in mostly all therapy areas except oncology. Therefore, having biomarker information is useful for separating individuals and ensuring that you treat an individual as an individual and can tailor their therapy. Most drugs do not work in all people.

Doctors 111

Doctors Clinical Trials Treatment Therapies 111

The Pharma Data

OCTOBER 26, 2020

ASTRO Issues Guideline on Radiation Therapy for Rectal Cancer. from Massachusetts General Hospital in Boston, and colleagues addressed four key questions focused on the use of RT in preoperative management of operable rectal cancer. MONDAY, Oct. Jennifer Y.

Therapies 52

Therapies Hospitals International Treatment 52

SCIENMAG: Medicine & Health

JULY 5, 2023

New insights explaining why some children have a longer remission than others after having cutting-edge CAR T-cell therapy for leukaemia have been revealed by researchers at UCL, Great Ormond Street Hospital, and the Wellcome Sanger Institute.

Treatment 69

Treatment Hospitals Therapies Research 69

Broad Institute

MARCH 8, 2024

Also, the genetic mechanisms of disease that we have identified offer the potential to guide development of curative therapies,” added co–lead author Aaron Deutsch, an instructor in the division of Endocrinology at MGH.

Medical Schools 127

Medical Schools Hospitals Disease Therapies 127

The Pharma Data

JANUARY 17, 2021

The Phase IIa POC studies will be conducted after a Phase Ib dose escalation study evaluating the tolerability and activity of proenzyme therapy in patients with advanced solid tumors is completed, planned for 2021, at the Peter Mac Cancer Center, Melbourne, Australia. For more information, please visit www.propanc.com.

Therapies 52

Therapies Clinical Trials Trials Hospitals 52

The Pharma Data

DECEMBER 3, 2020

In the long-term APeX-S trial, those who completed 48 weeks of therapy had an average attack rate of 0.8 ORLADEYO is the first and only oral therapy that was designed to prevent attacks of HAE in adults and pediatric patients age 12 and older. attacks per month at baseline, to a mean of 1.0 attacks per month. attacks per month.

FDA Approval 52

FDA Approval Therapies FDA Trials 52

Broad Institute

NOVEMBER 7, 2023

While RA therapies targeted to specific inflammatory pathways have emerged, only some patients’ symptoms improve with treatment, emphasizing the need for multiple treatment approaches tailored to different disease subtypes. Adapted from a press release issued by Brigham and Women's Hospital.

Treatment 96

Treatment RNA Hospitals Disease 96

Broad Institute

APRIL 2, 2024

Now, a team of researchers at the Broad Institute of MIT and Harvard along with Massachusetts General Hospital has found that microbes in the gut may affect cardiovascular disease as well. He is also a professor at Harvard Medical School and Massachusetts General Hospital.

Disease 145

Disease Medical Schools Hospitals DNA 145

Broad Institute

OCTOBER 23, 2024

The work highlights the importance of examining the often-ignored noncoding parts of the genome when diagnosing rare genetic disorders, and also points to possible future genetic therapies that fine-tune CHASERR abundance as a means to treat CHASERR - and CHD2 -related disorders.

DNA 128

DNA RNA Disease Hospitals 128

Drug Target Review

OCTOBER 1, 2024

At the beginning of my career, during my scholarship, I worked for two years at a research institute where I set up a research project focused on the study of metronomic oral therapies for patients with metastatic breast cancer (BC). That paper, of which I was in the authorship, remains a current point of reference for that therapy usage.

Doctors 97

Doctors Therapies Science Pharma Companies 97

Broad Institute

NOVEMBER 25, 2024

The L2C Accelerator is focused on vastly shortening the time to develop therapies for rare disease patients by grouping together hundreds (or even thousands) of rare genetic mutations in parallel and identifying many candidate therapeutic targets (i.e. Our vision is to uncover as many nodes as possible in a highly parallel manner.

Clinical Trials 52

Clinical Trials Disease Trials Therapies 52

The Pharma Data

MARCH 24, 2021

of women who continued on relugolix combination therapy remained responders (menstrual blood loss < 80 mL) through Week 76 compared with 15.1% of women who continued relugolix combination therapy remained responders through Week 104. of women who discontinued treatment at Week 52 (p < 0.0001). weeks after discontinuation.

Therapies 52

Therapies Treatment Science FDA Approval 52